UBS Lifts Johnson & Johnson Price Target to $320 Amid Strong Q2 Earnings

Johnson & Johnson (ISIN US4781601046) stock continued its rally in early September 2026, nearing record levels after a fresh analyst report highlighted faster growth in its pharmaceuticals pipeline and lifted a key Wall Street price target to $320.

The UBS price target increase drove sentiment, with the firm raising its target from $280 to $320 while reiterating a Buy rating. This represents an increase of about 14.3% in the target level, signaling greater confidence in Johnson & Johnson's medium-term earnings power.

In its most recent reported quarter, the company delivered a solid set of numbers that underpin the more optimistic stance. Johnson & Johnson's second-quarter 2026 results showed sales rising 6.6% year-on-year to $25.3 billion, a clear acceleration compared with the prior year period.

However, valuation metrics are stretched, with the stock trading about 44.1% above its intrinsic value estimate of $192.90 per share, according to GuruFocus. This valuation gap is central to the risk-reward discussion, highlighting that future share price gains will likely depend more on earnings delivery than on further multiple expansion.